no spam, unsubscribe anytime.
In a study published today in the Lancet, researchers suggest that some breast cancer patients would do better taking tamoxifen for ten years, instead of the normally prescribed five.
The research focused on oestrogen receptor (ER)-positive early breast cancer and concluded:
"For women with ER-positive disease, continuing tamoxifen to ten years rather than stopping at five years produces a further reduction in recurrence and mortality, particularly after year 10. These results, taken together with results from previous trials of 5 years of tamoxifen treatment versus none, suggest that ten years of tamoxifen treatment can approximately halve breast cancer mortality during the second decade after diagnosis."
The Lancet report is available online.